Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1368465 | PMC |
| http://dx.doi.org/10.1111/j.1365-2125.1991.tb05569.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
How do we measure the costs, benefits, and harms of sharing data from biomedical studies? A protocol for a scoping review.
Open Res Eur
January 2025
Heidelberger Institut für Global Health, Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, 69120, Germany.
Introduction: The benefits of sharing participant-level data, including clinical or epidemiological data, genomic data, high-dimensional imaging data, or human-derived samples, from biomedical studies have been widely touted and may be taken for granted. As investments in data sharing and reuse efforts continue to grow, understanding the cost and positive and negative effects of data sharing for research participants, the general public, individual researchers, research and development, clinical practice, and public health is of growing importance. In this scoping review, we will identify and summarize existing evidence on the positive and negative impacts and costs of data sharing and how they are measured.
View Article and Find Full Text PDFDual Biologic Therapy Induces Remission in Refractory Crohn's Disease With Vedolizumab and Ustekinumab.
Crohns Colitis 360
January 2025
Division of Digestive Diseases and Nutrition, Department of Medicine, University of Kentucky College of Medicine, Lexington, KY, USA.
Background: Despite advancements in the therapeutic armamentarium for Crohn's disease (CD), biologic and small molecule monotherapies are associated with sub-optimal response and remission rates. Utilizing dual biologic therapy (DBT) holds the potential to increase efficacy in the treatment of refractory or partially responsive CD. Evidence pertaining to this strategy remains limited.
View Article and Find Full Text PDFIntroduction: Benralizumab is an interleukin 5-receptor-blocking drug registered for the treatment of eosinophilic asthma. It has proven efficient and safe in a small phase-II trial in hypereosinophilic syndrome and is currently being investigated in a larger, randomized phase-III trial. We report on real-world experience with benralizumab in 15 patients with severe Hypereosinophilic syndrome (HES) that were refractory to other treatments or on unacceptable steroid doses.
View Article and Find Full Text PDFOverview of basic design recommendations for user-centered explanation interfaces for AI-based clinical decision support systems: A scoping review.
Digit Health
January 2025
Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
Objective: The application of artificial intelligence (AI)-based clinical decision support systems (CDSS) in the healthcare domain is still limited. End-users' difficulty understanding how the outputs of opaque black AI models are generated contributes to this. It is still unknown which explanations are best presented to end users and how to design the interfaces they are presented in (explanation user interface, XUI).
View Article and Find Full Text PDFThe design of retroviral vectors used in the CAR-T products, risk management, and future perspective.
MedComm (2020)
February 2025
Chimeric antigen receptor T-cell (CAR-T) therapy is a revolutionary approach in cancer treatment. More than 10 CAR-T products have already approved on market worldly wide, and they use either gamma retroviral vectors or lentiviral vectors to deliver the CAR gene. Both vectors have the ability to effectively and persistently integrate the CAR gene into T cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!